Athos Therapeutics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Athos Therapeutics is a UK clinical-stage biotech founded in 2019 using AI and systems biology to discover precision therapies for autoimmune and chronic inflammatory diseases;
About
Athos Therapeutics is a clinical-stage biotechnology company founded in 2019 and headquartered in the United Kingdom. The company's platform integrates artificial intelligence, medicinal chemistry, and systems biology to discover and develop novel therapeutics for patients with autoimmune and chronic inflammatory diseases. Rather than applying AI as a standalone tool, Athos has built an integrated computational-experimental workflow: machine learning models trained on systems biology data guide the identification and optimization of novel small-molecule and biologic drug candidates, which are then validated through in-house experimental chemistry.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.